The Democrats' new majority in the US Congress is already affecting biotechnology-related policies and programs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
The policy outlook from the Hill
US election: Showdown for Capitol Hill
Web links
Rights and permissions
About this article
Cite this article
Fox, J. Democrats prioritize pricing, generics and drug safety. Nat Biotechnol 25, 150–151 (2007). https://doi.org/10.1038/nbt0207-150
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0207-150